Copies of the questionnaire are available from the authors on request.
There are well documented guidelines for the control of oral anticoagulants in adults'; but oral anticoagulation of children is much less common. Little or no information is available on the use and particular problems associated with this treatment in childhood. We therefore undertook a survey of anticoagulant practice conducted by two groups of clinicians-haematologists and cardiologists or cardiac surgeons-involved in the initiation and control of oral anticoagulant treatment in children.
Methods
As a first step a questionnaire covering indications for use, optimal therapeutic ranges, and problems with warfarin treatment in children (up to age 14 years) was sent to 407 haematologists in Great Britain. Following analysis of their replies it became apparent that the largest group of children requiring oral anticoagulation were those with prosthetic cardiac valves. Therefore, a second modified questionnaire was sent to 77 consultants in 22 different centres specialising in paediatric cardiology and cardiothoracic surgery.
Copies of the questionnaire are available from the authors on request.
Results

QUESTIONNAIRE 1
Two hundred and thirty five out of 407 haematologists returned completed questionnaires. Of these, 173 (73 6%) had no record of children attending their anticoagulant clinics. The remaining 62 (26 4%) had controlled the warfarin treatment of 137 children during the previous five years. The age distribution and indications for anticoagulation of these patients are shown in tables 1 and 2.
In each age group a prosthetic cardiac valve was the most common indication for oral anticoagulation-that is, six of eight (75%) aged less than 2 years, 59 of 74 (79 7%) 2-10 years, 36 of 55 (65'5%) 10-14 years.
A summary of the stated target therapeutic ranges for oral anticoagulation in children with prosthetic heart valves and venous thrombosis (all causes) is shown in table 3. The intensities of anticoagulation are expressed as International Normalised Ratios (INR).
A further five haematologists indicated that their optimal level of anticoagulation in children with prosthetic heart valves was "the adult range."
In children under 2 years of age there were no stated differences in the desired degree of anticoagulation, for any disease group.
Three haematologists reported some difficulty with anticoagulant control. Two of these Evans, Rowlands, Poller Five centres reported no problems with anticoagulation and four reported some erratic control, three poor compliance, and one excessive bruising.
Data on patient numbers from all 11 centres were not available, but six departments reported that over the past five years 68 children with prosthetic heart valves had been anticoagulated with warfarin. There had been two clinically relevant bleeding episodes and two thrombotic episodes.
INITIATION OF ORAL ANTICOAGULATION IN CHLDREN
Seven of 63 (11 11%) haematologists reported that they used a specific formula for the induction of oral anticoagulant treatment in children. The remainder used no stated formula, or their patients began oral anticoagulant treatment elsewhere, normally in a cardiothoracic centre. No consistent pattern for the initiation of treatment was reported: each used a different method. The stated doses ranged from 0-1 to 1 0 mgm/kg/day or were recorded as one quarter the adult dose, or one half the adult dose. Of the 11 cardiothoracic centres, only eight replied to the question, three used a formula, and five did not. Two used the same formula-that is, 200 pg/kg warfarin a day for two days, then 100 pg/kg/day for one day, subsequent doses being govemed by the INR measured on day 4.
TESTS USED FOR CONTROL OF ANTICOAGULANTS
One hundred and eight (78 8%) children were controlled with a venous prothrombin time and 29 (212%) with a capillary test. Only a few children under the age of 2 were treated with anticoagulants; but of these, 50% were controlled with a capillary test.
Discussion
Most anticoagulant clinics supervised by haematologists do not treat children. Only three of the 62 reported in this study had seen five or more children in the previous five years.
The most common indication for anticoagulation in children of all ages is a prosthetic heart valve. The overall desired range of anticoagulation for these patients (INR 2-7-4 0) is slightly less intense anticoagulation than the recommended BSH guideline values (INR 3-0-4-5) for adults with similar conditions. In the absence of a BSH guideline recommendation for oral anticoagulation in children it must be inferred that most clinicians based their anticoagulant control on their experience with adult patients. The overall optimal range of anticoagulation for children with prosthetic heart valves as reported by specialists in cardiac care was 2-6-3-8 INR.
A similar situation with established venous thrombosis (overall target therapeutic range 2-1-3-25) probably exists.
No single dosage regimen can be recommended for the induction of oral anticoagulant treatment in children. The replies were too few and too variable for a consensus to have become apparent.
The questionnaire survey indicates that most children with prosthetic cardiac valves and thrombotic disorders are treated with levels of anticoagulation similar to those currently recommended for adults with the same conditions. A recent survey of adults with mechanical prosthetic heart valves controlled with a rabbit brain thromboplastin (Simplastin) 
